Santhera Pharmaceuticals Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Santhera Pharmaceuticals Holding hat ein Gesamteigenkapital von CHF59.9M und eine Gesamtverschuldung von CHF20.9M, wodurch sich der Verschuldungsgrad auf 34.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CHF109.6M bzw. CHF49.7M. Santhera Pharmaceuticals Holding Das EBIT des Unternehmens beträgt CHF51.2M, so dass der Zinsdeckungsgrad 2.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CHF30.4M.

Wichtige Informationen

34.9%

Verhältnis von Schulden zu Eigenkapital

CHF 20.94m

Verschuldung

Zinsdeckungsgrad	2.5x
Bargeld	CHF 30.37m
Eigenkapital	CHF 59.94m
Gesamtverbindlichkeiten	CHF 49.69m
Gesamtvermögen	CHF 109.63m

Jüngste Berichte zur Finanzlage

Recent updates

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Jun 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: SANNDie kurzfristigen Aktiva des Unternehmens (CHF34.7M) decken seine kurzfristigen Passiva (CHF44.3M) nicht.

Langfristige Verbindlichkeiten: SANNDie kurzfristigen Vermögenswerte des Unternehmens (CHF34.7M) übersteigen seine langfristigen Verbindlichkeiten (CHF5.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: SANN über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: SANN Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 196.1% auf 34.6% zurückgegangen.

Schuldendeckung: SANNDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (225.7%).

Zinsdeckung: SANNDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (2.5x Deckung) nicht gut gedeckt.

Santhera Pharmaceuticals Holding Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Recent updates

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

New minor risk - Market cap size

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Price target increased to CHF7.00

Forecast to breakeven in 2024

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

Price target decreased to CHF4.75

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Consensus revenue estimates increase to CHF16.8m

Price target increased to CHF6.23

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company

Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2020 Final Results on Apr 27, 2021

New 90-day high: CHF3.20

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development

New 90-day low: CHF3.29

Analysts increase EPS estimates to -CHF3.25

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone

New 90-day low: CHF6.22

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy

First half earnings released

Santhera Pharmaceuticals Holding AG to Report First Half, 2020 Results on Sep 08, 2020

New 90-day low - CHF6.44

New 90-day low - CHF7.05

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz